TY - JOUR
AU1 - Koo, Otilia
AU2 - Rubinstein, Israel
AU3 - Önyüksel, Hayat
AB - We propose that CPT-SSM-VIP is a promising targeted nanomedicine and should be further developed as a safe, long-acting, disease-modifying pharmaceutical product for RA.
TI - Actively Targeted Low-Dose Camptothecin as a Safe, Long-Acting, Disease-Modifying Nanomedicine for Rheumatoid Arthritis
JF - Pharmaceutical Research
DO - 10.1007/s11095-010-0330-4
DA - 2010-12-04
UR - https://www.deepdyve.com/lp/springer-journals/actively-targeted-low-dose-camptothecin-as-a-safe-long-acting-disease-MLTojQ4Wb5
SP - 776
EP - 787
VL - 28
IS - 4
DP - DeepDyve
ER -